Study wrapper · #1104
Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.
Silverii GA, Velardi V, Marinelli C, et al. Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.71128PubMed: 42530338
Editor's note
A large network meta-analysis placing tirzepatide among the diabetes agents associated with reduced cardiovascular events and mortality, with moderate-to-high certainty of evidence. Tirzepatide is one of several drug classes compared, so the finding is class-contextual rather than tirzepatide-specific.
Plain-language abstract
This network meta-analysis of 93 randomized trials found that tirzepatide, along with GLP-1 receptor agonists and SGLT2 inhibitors, was associated with reduced major cardiovascular events and lower all-cause mortality versus placebo. Tirzepatide is one of several agents examined rather than the sole focus.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Weak / none
Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.
Obesity pillarsn=——2026